medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2018, Number 1

<< Back Next >>

Ann Hepatol 2018; 17 (1)

Extending a Helping Hand: Addressing Hepatitis C in Economic Migrants and Refugees

Feld JJ

Language: English
References: 13
Page: 8-10
PDF size: 107.10 Kb.


Text Extraction

Despite remarkable progress in the development of new antiviral therapies, hepatitis C virus (HCV) remains an enormous global public health problem. Although cure is the new norm with direct-acting antivirals (DAAs) and treatment uptake hit record highs in 2016, the global burden of disease has inched very modestly downwards. Looking at global data, projections for 2017 are disheartening. Although an estimated 1.5 million people will be cured and another 350,000 will die from HCV while another 1.04 million HCV-infected individuals die of other causes, a staggering 1.6 million new infections are expected to occur, meaning that even in the year with the highest treatment rates ever recorded for HCV, the global prevalence is expected to dip by just 1.8%, from 71 to 68.8 million infected individuals (Andrew Hill, World Hepatitis Summit, São Paulo 2017). To achieve the ambitious elimination targets set out by the World Health Organization (WHO) of a 90% reduction in new infections and a 65% reduction in mortality from viral hepatitis by 2030, significant scale up of our current efforts will be required. Effective therapy was critical to even consider elimination but it is important to recognize that therapy is necessary but entirely insufficient on its own to achieve elimination.


REFERENCES

  1. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. The lancet Gastroenterology & hepatology 2017; 2: 161-76.

  2. Degenhardt L, Peacock A, Colledge S, Leung J, Grebely J, Vickerman P, Stone J, et al. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. The Lancet Global Health 2017; 5: e1192-e1207.

  3. Greenaway C, Thu Ma A, Kloda LA, Klein M, Cnossen S, Schwarzer G, Shrier I. The Seroprevalence of Hepatitis C Antibodies in Immigrants and Refugees from Intermediate and High Endemic Countries: A Systematic Review and Meta-Analysis. PloS One 2015, 10: e0141715.

  4. Xiong H, Rong X, Wang M, Xu R, Huang K, Liao Q, Huang J, et al. HBV/HCV co-infection is associated with a high level of HCV spontaneous clearance among drug users and blood donors in China. J Viral Hepat 2017; 24: 312-9.

  5. Linas BP, Barter DM, Leff JA, Assoumou SA, Salomon JA, Weinstein MC, Kim AY, et al. The hepatitis C cascade of care: identifying priorities to improve clinical outcomes. PloS One 2014; 9: e97317.

  6. Bajis S, Dore GJ, Hajarizadeh B, Cunningham EB, Maher L, Grebely J. Interventions to enhance testing, linkage to care and treatment uptake for hepatitis C virus infection among people who inject drugs: A systematic review. Int J Drug Policy 2017; 47: 34-46.

  7. Yehia BR, Schranz AJ, Umscheid CA, Lo Re V, 3rd. The treatment cascade for chronic hepatitis C virus infection in the United States: a systematic review and meta-analysis. PloS One 2014; 9: e101554.

  8. Mera J, Vellozzi C, Hariri S, Carabin H, Drevets DA, Miller A, Reilley B, et al. Identification and Clinical Management of Persons with Chronic Hepatitis C Virus Infection - Cherokee Nation, 2012-2015. MMWR 2016; 65: 461-6.

  9. Wong WW, Woo G, Jenny Heathcote E, Krahn M. Cost effectiveness of screening immigrants for hepatitis B. Liv Int 2011; 31: 1179-90.

  10. Marshall AD, Cunningham EB, Nielsen S, Aghemo A, Alho H, Backmund M, Bruggmann P, et al. Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe. The Lancet Gastroenterology & Hepatology 2017.

  11. Barua S, Greenwald R, Grebely J, Dore GJ, Swan T, Taylor LE. Restrictions for Medicaid Reimbursement of Sofosbuvir for the Treatment of Hepatitis C Virus Infection in the United States. Ann Int Med 2015; 163: 215-23.

  12. La Spada E, Soresi M, Giannitrapani L, La Spada M, Campagna E, Terranova A, Cartabellotta F, et al. Long-term follow- up of hepatitis C virus-positive patients with persistently normal serum transaminases. Ann Hepatol 2013; 12: 36-43.

  13. Xiao G, Zhu S, Xiao X, Yan L, Yang J, Wu G. Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: A meta-analysis. Hepatology 2017; 66: 1486-1501.




2020     |     www.medigraphic.com